Skip to content
Aussie8 – Lifestyle
Author:
Apogee Therapeutics
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
May 27, 2026
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
May 27, 2026
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
May 26, 2026
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
May 11, 2026
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
March 24, 2026
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
March 23, 2026
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
March 23, 2026
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
March 22, 2026